The use of orthokine therapy for the treatment of post refractive surgery corneal ulcer, a case report.

[1]  G. Qin,et al.  Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials , 2023, Journal of Orthopaedic Surgery and Research.

[2]  Evan.  The Biologic Approach for Managing Cartilage Injury: Where are We Now™ , 2023, Orthopaedic Journal of Sports Medicine.

[3]  S. Dow,et al.  In Vitro Anti-Inflammatory and Regenerative Effects of Autologous Conditioned Serum from Dogs with Osteoarthritis , 2022, Animals : an open access journal from MDPI.

[4]  M. Yousefi,et al.  The therapeutic effects of autologous conditioned serum on knee osteoarthritis: an animal model , 2022, BMC research notes.

[5]  S. Shakouri,et al.  Autologous conditioned serum (Orthokine) injection for treatment of classical trigeminal neuralgia: results of a single-center case series , 2022, Journal of Medical Case Reports.

[6]  R. Sitompul,et al.  Amniotic membrane transplantation for infectious corneal ulcer treatment: a cohort retrospective study , 2020, Medical Journal of Indonesia.

[7]  Afsaneh Vazin,et al.  A study on the most prevalent bacterial cause of corneal ulcer and their susceptibility to five common types of ophthalmic antibiotics , 2020 .

[8]  D. Golicki,et al.  Evaluation of the Effectiveness of Orthokine Therapy: Retrospective Analysis of 1000 Cases. , 2020, Ortopedia, traumatologia, rehabilitacja.

[9]  R. Porter,et al.  Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture , 2019, Arthritis Research & Therapy.

[10]  Bing Zhang,et al.  IL-1β receptor antagonist (IL-1Ra) combined with autophagy inducer (TAT-Beclin1) is an effective alternative for attenuating extracellular matrix degradation in rat and human osteoarthritis chondrocytes , 2019, Arthritis Research & Therapy.

[11]  N. Damjanov,et al.  The efficacy and safety of autologous conditioned serum (ACS) injections compared with betamethasone and placebo injections in the treatment of chronic shoulder joint pain due to supraspinatus tendinopathy: a prospective, randomized, double-blind, controlled study. , 2018, Medical ultrasonography.

[12]  L. Tártara,et al.  Treatment of corneal ulcers with platelet rich plasma , 2014 .

[13]  S. Masiero,et al.  Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders. , 2013, British medical bulletin.

[14]  C. Botsios.  Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.

[15]  P. Wehling,et al.  Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. , 2004, International journal of sports medicine.

[16]  Xiaoling Zhang,et al.  Suppression of early experimental osteoarthritis by gene transfer of interleukin‐1 receptor antagonist and interleukin‐10 , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[17]  P. Wehling,et al.  The production of anti-inflammatory cytokines in whole blood by physico-chemical induction , 2003, Inflammation Research.

[18]  V. Durairaj,et al.  Infectious keratitis after laser refractive surgery. , 2001, Ophthalmology.

[19]  M. Srinivasan,et al.  Corneal ulceration in the developing world—a silent epidemic , 1997, The British journal of ophthalmology.

[20]  N. Srivastava,et al.  “Etiology, Risk Factor, Diagnosis and Treatment Outcome of Fungal Corneal Ulcer in Tertiary Care Centre” , 2020 .

[21]  M. Abbasian,et al.  Comparison of the Effect of Intra-Articular Injection of Autologous (Orthokine) Interleukin-1 Receptor Antagonist (IL-1Ra) and Hyaluronic Acid in Pain Control of Knee Osteoarthritis , 2019 .

[22]  M.L.V. de Mello,et al.  Treatment of Corneal Ulcer Complicated In Domestic Canine, With the Complementary Use of Homeopathy, Moxabustion and Autologous Serum , 2018 .

[23]  C. McIlwraith,et al.  Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene , 2002, Gene Therapy.